drugset

drugset / Trial / NCT01200498

Study of SB939 in Subjects With Myelofibrosis

NCT01200498 ↗

Phase 2 Completed 23 enrolled M.D. Anderson Cancer Center S*BIO · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.

Timeline

Start: 2010-11
Primary completion: 2012-11
Completion: 2012-11

Publications

Results Quintas-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep;36(9):1124-7. doi: 10.1016/j.leukres.2012.03.003. Epub 2012 Apr 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pracinostat	Other / unclassified	60 mg	Oral

Indications